BadassBlues
Well-Known Member
I was going to order a few things today and when I went to their site, this was displayed:
www.peptidesciences.com
Let’s be direct about what likely happened here, because the industry commentary is dancing around it.
Peptide Sciences built a business that, by all available e-commerce data, generated revenue in the hundreds of millions of dollars over its lifetime. They did this by selling research chemicals in a regulatory gray zone where enforcement was sporadic and penalties were manageable.
Then three things changed simultaneously:
As we noted in our initial analysis on X: “Peptide Sciences made a quarter billion and walked away at the top. Why fight the FDA in court for a decade when you can just close the laptop and retire? Smartest exit in the gray market.”
This isn’t a tragedy. It’s a business decision.
Buy Peptides for Scientific Research and Development.
Buy Peptides for Scientific Research and Development. Peptide Sciences™ specializes in the synthesis of highly purified peptides, proteins and amino acid derivatives for scientific research and development.
www.peptidesciences.com
The Smartest Exit in the Gray Market
Let’s be direct about what likely happened here, because the industry commentary is dancing around it.
Peptide Sciences built a business that, by all available e-commerce data, generated revenue in the hundreds of millions of dollars over its lifetime. They did this by selling research chemicals in a regulatory gray zone where enforcement was sporadic and penalties were manageable.
Then three things changed simultaneously:
- The highest-margin products (GLP-1s) became legally untouchable. New legislation and 50+ warning letters made continued sales of semaglutide, tirzepatide, and retatrutide an invitation to federal prosecution rather than a calculated risk.
- The enforcement apparatus escalated from letters to raids. Amino Asylum getting their warehouse raided by the FDA in June 2025 sent a message that the era of “we’ll send you a letter and you’ll ignore it” was over.
- The quality facade cracked. Independent testing from Finnrick exposed product quality issues that undermined the brand’s core value proposition: that you were getting pharmaceutical-grade products from a scientifically rigorous supplier.
As we noted in our initial analysis on X: “Peptide Sciences made a quarter billion and walked away at the top. Why fight the FDA in court for a decade when you can just close the laptop and retire? Smartest exit in the gray market.”
This isn’t a tragedy. It’s a business decision.
